Target Name: HPN-AS1
NCBI ID: G100128675
Review Report on HPN-AS1 Target / Biomarker Content of Review Report on HPN-AS1 Target / Biomarker
Other Name(s): HPN antisense RNA 1, transcript variant 1 | HPN antisense RNA 1 | HPN-AS1 variant 1

Introduction to HPN-AS1
HPN-AS1 (Hepsin Pseudogene 1) is a long non-coding RNA (lncRNA) that has recently gained significant attention in the field of cancer research as a potential drug target and biomarker. This article aims to explore the various aspects of HPN-AS1, encompassing its structure, function, role in cancer, and the potential therapeutic implications it presents.

The Structure and Function of HPN-AS1:
HPN-AS1 is a lncRNA located on chromosome 19q13.2 and is transcribed from the antisense strand of the hepsin (HPN) gene. It is comprised of over 3000 nucleotides and lacks protein-coding potential. Despite being labeled as a pseudogene due to its inability to produce functional proteins, HPN-AS1 plays a critical role in various cellular processes.

Studies have shown that HPN-AS1 acts as a competing endogenous RNA (ceRNA), binding to microRNAs (miRNAs) and preventing their interaction with target messenger RNAs (mRNAs). This ceRNA mechanism allows HPN-AS1 to regulate the expression of numerous genes involved in cancer progression, such as those associated with cell cycle control, apoptosis, migration, and invasion.

HPN-AS1 as a Biomarker:
Several research studies have reported aberrant expression levels of HPN-AS1 in various cancer types, including hepatocellular carcinoma (HCC), colorectal cancer, gastric cancer, and lung cancer. The dysregulation of HPN-AS1 frequently correlates with tumor stage, metastasis, and overall patient survival, indicating its potential as a valuable biomarker for diagnostic and prognostic purposes.

In HCC, for instance, HPN-AS1 expression is significantly upregulated compared to healthy liver tissues. High levels of HPN-AS1 have been associated with advanced tumor stage, increased tumor size, and poor patient prognosis. Similarly, in lung cancer, elevated expression of HPN-AS1 is seen in both tumor tissues and plasma samples of patients with metastasis, highlighting its potential as a non-invasive biomarker for early cancer detection and monitoring treatment response.

The Role of HPN-AS1 in Cancer:
Emerging evidence suggests that HPN-AS1 plays a crucial role in cancer development and progression by regulating various molecular mechanisms. In hepatocellular carcinoma, HPN-AS1 promotes tumor growth and metastasis by inhibiting the tumor suppressor miR-203a-3p and activating the IL-11/STAT3 signaling pathway. Additionally, in gastric cancer, HPN-AS1 upregulation promotes the proliferation, migration, and invasion of cancer cells by acting as a sponge for miR-124-3p and enhancing the expression of its downstream target genes.

Furthermore, studies have demonstrated that HPN-AS1 governs epithelial-mesenchymal transition (EMT) in cancer cells, a critical process involved in metastasis. By sequestering miR-145-5p, HPN-AS1 enhances the expression of ZEB1, a transcription factor associated with EMT, thereby promoting cancer cell invasion and metastasis.

Therapeutic Implications and Conclusion:
The dysregulation of HPN-AS1 and its functional involvement in cancer progression highlight its potential as a therapeutic target for various types of cancer. By targeting HPN-AS1, researchers could potentially inhibit its ceRNA activity and restore the normal expression levels of tumor suppressor genes, thus suppressing cancer growth and metastasis.

Furthermore, the aberrant expression of HPN-AS1 makes it a promising biomarker for cancer diagnosis, prognosis, and treatment monitoring. Its presence in easily accessible biological samples, such as blood plasma, adds to its appeal as a non-invasive diagnostic tool that could facilitate early cancer detection and enable personalized treatment strategies.

In conclusion, HPN-AS1 is a fascinating lncRNA that holds immense potential as both a drug target and a biomarker in cancer research. Further investigations into its underlying molecular mechanisms and clinical utility are necessary to fully harness its therapeutic implications and enhance cancer management strategies.

Protein Name: HPN Antisense RNA 1

The "HPN-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HPN-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

HPR | HPRT1 | HPRT1P2 | HPS1 | HPS3 | HPS4 | HPS5 | HPS6 | HPSE | HPSE2 | HPX | HPYR1 | HR | HRAS | HRC | HRCT1 | HRG | HRH1 | HRH2 | HRH3 | HRH4 | HRK | HRNR | HROB | HS1BP3 | HS1BP3-IT1 | HS2ST1 | HS3ST1 | HS3ST2 | HS3ST3A1 | HS3ST3B1 | HS3ST4 | HS3ST5 | HS3ST6 | HS6ST1 | HS6ST2 | HS6ST3 | HSBP1 | HSBP1L1 | HSCB | HSD11B1 | HSD11B1-AS1 | HSD11B1L | HSD11B2 | HSD17B1 | HSD17B1-AS1 | HSD17B10 | HSD17B11 | HSD17B12 | HSD17B13 | HSD17B14 | HSD17B1P1 | HSD17B2 | HSD17B3 | HSD17B4 | HSD17B6 | HSD17B7 | HSD17B7P1 | HSD17B7P2 | HSD17B8 | HSD3B1 | HSD3B2 | HSD3B7 | HSD3BP4 | HSD3BP5 | HSD52 | HSDL1 | HSDL2 | HSDL2-AS1 | HSF1 | HSF2 | HSF2BP | HSF4 | HSF5 | HSFX1 | HSFX2 | HSFX3 | HSFY1 | HSFY1P1 | HSFY2 | HSH2D | HSP90AA1 | HSP90AA2P | HSP90AA3P | HSP90AA4P | HSP90AA5P | HSP90AA6P | HSP90AB1 | HSP90AB2P | HSP90AB3P | HSP90AB4P | HSP90B1 | HSP90B2P | HSP90B3P | HSPA12A | HSPA12B | HSPA13 | HSPA14 | HSPA1A | HSPA1B